Submit your iPLEDGE story

Patients, physicians, and pharmacists have faced considerable challenges completing the prescribing process using iPLEDGE, a risk management program required by the FDA to prevent exposure to the drug during pregnancy.

The American Academy of Dermatology Association is advocating vigorously with the FDA and drug manufacturers to make necessary changes to iPLEDGE to improve access to isotretinoin. We’d like to hear from patients about the impact iPLEDGE program is having on your care and what the loss of your treatment will mean for you. General information will be shared with stakeholders to help us restore access to treatment while maintaining patient safety. No personal information about you is being collected or shared.